Influence of Leukotriene Pathway Polymorphism on Responsiveness to Montelukast, Budesonide Plus Formoterol in Patients with Asthma
Keywords:
Asthma, Montelukast, ALOX5 SNP, Budesonide / Formoterol Inhalation Powder, PolymorphismsAbstract
Variability between patients in response to montelukast, and budesonide / formoterol inhalation powder may be related to genetic variation and non-genetic factors. this paper aims to determine association between polymorphism in leukotriene pathway candidate gene with lung function outcomes in Iraqi patients with asthma receiving montelukast, budesonide plus formoterol inhaler in comparison with healthy control. This research was done on a study group of 80 Baghdad-based Iraqi patients. 40 asthmatic patients receiving montelukast were in the first group, while 40 asthmatic patients on budesonide / formoterol inhalation powder (160/4.5mcg/dose) were in the second group. Screening for the presence of ALOX5 rs2115819, LTA4H rs2660845 and CysLTR1 rs320995 SNPs allelic variants genes were determined using conventional PCR technique and sequencing. In montelukast group, the % change in FEV1 in patients with the GG genotype for ALOX5 (rs2115819) SNP were significantly improved after montelukast intake compared with those carrying AA or AG genotypes. For budesonide / formoterol inhalation powder patients group, the included polymorphism had no significant association with the %change in FEV1. As a conclusion Asthmatic patients carrying AA genotype for ALOX5 rs2115819 may not achieved the optimal response to montelukast treatment. Budesonide / formoterol inhalation powder cannot be used effectively in patients with ALOX5 rs2115819 polymorphism.
References
Drazen, J., and Austen, K. (1987). Leukotrienes and Airway Responses, American Review of Respiratory Disease, 136(4), pp. 985-998.
Gauvreau G., El-Gammal A., and O'Byrne P. (2015). Allergen-induced Airway Responses, The European Respiratory Journal, 46(3), pp. 819-831.
GINA (2021). Global Initiative for Asthma Report, Global Strategy for Asthma Management and Prevention.
Kotani, H., Kishi, R., Mouri, A., Sashio, T., Shindo, J., Shiraki, A., Hiramatsu, T., Iwata, S., Taniguchi, H., Nishiyama, O., Iwata, M., Suzuki, R., Gonda, H., Niwa, T., Kondo, M., Hasegawa, Y., Kume, H., and Noda, Y. (2012). Influence of Leukotriene Pathway Polymorphisms on Clinical Responses to Montelukast in Japanese Patients with Asthma, Journal of Clinical Pharmacy and Therapeutics, 37(1), pp. 112–116.
Lima, J., Zhang, S., Grant, A., Shao, L., Tantisira, K., Allayee, H., Wang, J., Sylvester, J., Holbrook, J., Wise, R., Weiss, S., and Barnes, K. (2006). Influence of Leukotriene Pathway Polymorphisms on Response to Montelukast in Asthma, American Journal of Respiratory and Critical Care Medicine, 173, pp. 379–385.
Mougey, E., Lang, J., Allayee H., W G Teague, W., Dozor, A., Wise, R., and Lima, J. (2013). ALOX 5 Polymorphism Associates with Increased Leukotriene Production and Reduced Lung Function and Asthma Control in Children with Poorly Controlled Asthma, Clinical and Experimental Allergy, 43(5), pp. 512-520.
Woods, J., Evans, J., Ethier, D., Scott, S., Vickers, P., Hearn, L., and Singer, I. (1993). 5-lipoxygenase and 5-lipoxygenase-Activating Protein are Localized in the Nuclear Envelope of Activated Human Leukocytes, The Journal of Experimental Medicine, 178(6), pp. 1935-1946.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Journal of Prospective Researches
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
